Insights into mu opioid pharmacology: The role of mu opioid receptor subtypes

Life Sciences

Volumn 68, Issue 19-20, 2001, Pages 2213-2219

  Pasternak, Gavril W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

MOR 1; Morphine; Morphine 6 glucuronide; Mu opioid receptor; Splicing

Indexed keywords

DIAMORPHINE; FENTANYL; M6G; MORPHINE; MU OPIATE RECEPTOR; NALOXAZONE; NALOXONAZINE; OPIATE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; DRUG CROSS TOLERANCE; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; MOLECULAR CLONING; NONHUMAN; PROTEIN VARIANT; RNA SPLICING;

EID: 0035815179     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01008-6     Document Type: Conference Paper

References (48)

1. Reisine T and Pasternak GW, Opioid analgesics and antagonists, J.G. Hardman and L.E. Limbird (Eds), Goodman & Gilman's: The Pharmacological Basis of Therapeutics, McGraw-Hill, 1996. pp. 521-556.
2. Crews JC, Sweeney NJ, and Denson DD. Clinical efficacy of methadone in patients refractory to other muopioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993;72:2266-72.
3. Galer BS, Coyle N, Pasternak GW, and Portenoy RK. Individual variability in the response to different opioids: Report of five cases. Pain 1992;49:87-91
4. Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999;86:1856-66
5. Payne R and Pasternak GW, Pain, M.V. Johnston, R.L. Macdonald, and A.B. Young (Eds), Principles of Drug Therapy in Neurology, Philadelphia: F.A. Davis, 1992. pp. 268-301.
6. Baron A, Shuster L, Elefterhiou BE, and Bailey DW. Opiate receptors in mice: Genetic differences. Life Sci. 1975;17:633-40
7. Reith MEA, Sershen H, Vadasz C, and Lajtha A. Strain differences in opiate receptors in mouse brain. Eur. J. Pharmacol. 1981;74:377-80
8. Pick CG, Nejat R, and Pasternak GW. Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains. J.Pharmacol.Exp.Ther. 1993;2265:166-71
9. Chang A, Emmel DW, Rossi GC, and Pasternak GW. Methadone analgesia in morphine-insensitive CXBK mice. Eur.J.Pharmacol. 1998;351:189-91
10. Rossi GC, Brown GP, Leventhal L, Yang K, and Pasternak GW. Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci.Lett. 1996;216:1-4
11. Pasternak GW and Snyder SH. Identification of a novel high affinity opiate receptor binding in rat brain. Nature 1975;253:563-5
12. Pasternak GW, Childers SR, and Snyder SH. Opiate analgesia: Evidence for mediation by a subpopulation of opiate receptors. Science 1980;208:514-6
13. Pasternak GW, Childers SR, and Snyder SH. Naloxazone, long-acting opiate antagonist: Effects in intact animals and on opiate receptor binding in vitro. J.Pharmacol.Exp.Ther. 1980;214:455-62
14. Wolozin BL and Pasternak GW. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc.Natl.Acad.Sci.USA 1981;78:6181-5
15. Hahn EF, Carroll-Buatti M, and Pasternak GW. Irreversible opiate agonists and antagonists: The 14-hydroxydihydromorphinone azines. J.Neurosci. 1982;2:572-6
16. Ling GSF and Pasternak GW. Spinal and supraspinal opioid analgesia in the mouse: The role of subpopulations of opioid binding sites. Brain Res. 1983;271:152-6
17. Ling GSF, Spiegel K, Nishimura S, and Pasternak GW. Dissociation of morphine's analgesic and respiratory depressant actions. Eur.J.Pharmacol. 1983;86:487-8
18. Ling GSF, Spiegel K, Lockhart SH, and Pasternak GW. Separation of opioid analgesia from respiratory depression: Evidence for different receptor mechanisms. J.Pharmacol.Exp.Ther. 1985;232:149-55
19. Paul D, Bodnar RJ, Gistrak MA, and Pasternak GW. Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur.J.Pharmacol. 1989;129:307-14
20. Heyman JS, Williams CL, Burks TF, Mosberg HI, and Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: Studies with naloxonazine. J.Pharmacol.Exp.Ther. 1988;245:238-43
21. Kiefel JM, Cooper ML, and Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res. 1992;597:331-8
22. Paul D and Pasternak GW. Differential blockade by naloxonazine of two μ opiate actions: Analgesia and inhibition of gastrointestinal transit. Eur.J.Pharmacol. 1988;149:403-4
23. Ling GSF, Paul D, Simantov R, and Pasternak GW. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci. 1989;45:1627-36
24. Spiegel K, Kourides I, and Pasternak GW. Prolactin and grwoth hormone release by morphine in the rat: Different eceptor mechanisms. Science 1982;217:745-7
25. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin.Neuropharmacol. 1993;16:1-18
26. Pasternak GW, Bodnar RJ, Clark JA, and Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987;41:2845-9
27. Paul D, Standifer KM, Inturrisi CE, and Pasternak GW. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J.Pharmacol.Exp.Ther. 1989;251:477-83
28. Brown GP, Yang K, King MA, Rossi GC, Leventhal L, Chang A, and Pasternak GW. 3-Methoxynaltrexone, a selective heroin/morphine-6β-glucuronide antagonist. FEBS Lett. 1997;412:35-8
29. Walker JR, King M, Izzo E, Koob GF, and Pasternak GW. Antagonism of heroin and morphine self-administration in rats by the morphine-6β-glucuronide antagonist 3-0-methylnaltrexone. Eur.J.Pharmacol. 1999;383:115-9
30. Chen Y, Mestek A, Liu J, Hurley JA, and Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol.Pharmacol. 1993;44:8-12
31. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, and Uhl GR. μ opiate receptor: cDNA cloning and expression. Proc.Natl.Acad.Sci.USA 1993;90:10230-4
32. Rossi GC, Pan Y-X, Cheng J, and Pasternak GW. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 1994;54:PL375-9
33. Chen XH, Adams JU, Geller EB, Deriel JK, Adler MW, and Liu-Chen L-Y. An antisense oligodeoxynucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats. Eur.J.Pharmacol. 1995;275:105-8
34. Rossi GC, Pan Y-X, Brown GP, and Pasternak GW. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett. 1995;369:192-6
35. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, and Pasternak GW. Antisense mapping of MOR-1 in the rat: Distinguishing between morphine and morphine-6β-glucuronide antinociception. J.Pharmacol.Exp.Ther. 1997;281:109-14
36. Standifer KM, Chien C-C, Wahlestedt C, Brown GP, and Pasternak GW. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron 1994;12:805-10
37. Standifer KM, Jenab S, Su W, Chien C-C, Pan Y-X, Inturrisi CE, and Pasternak GW. Antisense oligodeoxynucleotides to the cloned δ receptor, DOR-1: Uptake, stability and regulation of gene expression. J.NeuroChem. 1995;65:1981-7
38. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, and Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996;383:819-23
39. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, and Uhl GR. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc.Natl.Acad.Sci.USA 1997;94:1544-9
40. Loh HH, Liu HC, Cavalli A, Yang WL, Chen YF, and Wei LN. μ opioid receptor knockout in mice: Effects on ligand-induced analgesia and morphine lethality. Mol.Brain Res. 1998;54:321-6
41. Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, Pasternak GW, and Pintar JE. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat.Neurosci. 1999;2:151-6
42. Bare LA, Mansson E, and Yang D. Expression of two variants of the human μ opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 1994;354:213-6
43. Zimprich A, Simon T, and Hollt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR 1 B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 1995;359:142-6
44. Pan YX, Xu J, Bolan EA, Abbadie C, Chang A, Zuckerman A, Rossi GC, and Pasternak GW. Identification and characterization of three new alternatively spliced mu opioid receptor isoforms. Mol.Pharmacol. 1999;56:396-403
45. Pan Y-X, Xu J, Bolan EA, Chang A, Mahurter L, Rossi GC, and Pasternak GW. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F. FEBS Lett. 2000;466:337-40
46. Abbadie C, Pan Y-X, and Pasternak GW. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C and MOR-1-like immunoreactivity: Evidence for region-specific processing. J.Comp.Neurol. 2000;419:244-56
47. Abbadie C, Pan Y-X, Drake CT, and Pasternak GW. Comparative distribution of the mu opioid receptor splice variant MOR-1D-like immunoreactivity with MOR-1- and MOR-1C-like immunoreactivities in the murine central nervous system. Neuroscience 2000;100:141-53
48. Abbadie C, Gultekin SH, and Pasternak GW. Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport 2000;11:1-5